Kazumoto Murata

TL;DR: HBV-expressing hepatocytes produce endoplasmic reticulum (ER)-associated endogenous antigenic lipids including lysophospholipids that are generated by HBV-induced secretory phospholipases and that lead to activation of natural killer T (NKT) cells, which may contribute to control of HBV infection through sensing of HBv-induced modified self-lipids.

TL;DR: The results suggest that HCV-LPs can induce humoral and cellular immune responses that are protective in a surrogate HCV challenge model and that a strong cellular immunity provided by both CD4 and CD8 effector lymphocytes may be important for protection from HCV infection.

TL;DR: YKL-40 may be a useful non-invasive serum marker to estimate the degree of liver fibrosis and to evaluate the efficacy of IFN therapies in patients with HCV-associated liver disease.

TL;DR: It is found that pretreatment with IL-1β and TNFα remarkably reduced the host cell susceptibility to HBV infection, and this effect was mediated by activation of the NF-κB signaling pathway.

TL;DR: It is discovered that the nucleotide analogues show an additional pharmacological effect by inducing IFN-λ3 production, which further induces ISGs and results in a reduction of HBsAg production.